Blume Capital Management, Inc. Biogen Inc. Transaction History

Blume Capital Management, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 May 01, 2024	SELL	$275.25 - $318.06 $7,982 - $9,223	-29 Reduced 53.7%	25 $7,000
Q2 2023 Aug 10, 2023	SELL	$275.25 - $318.06 $7,982 - $9,223	-29 Reduced 53.7%	25 $7,000
Q1 2023 May 01, 2024	BUY	$256.56 - $292.34 $13,854 - $15,786	54 New	54 $15,000
Q1 2023 May 08, 2023	BUY	$256.56 - $292.34 $6,670 - $7,600	26 Added 92.86%	54 $15,000
Q3 2022 Nov 15, 2022	SELL	$194.69 - $268.46 $10,902 - $15,033	-56 Reduced 66.67%	28 $7,000
Q2 2022 Aug 11, 2022	BUY	$187.54 - $223.02 $2,062 - $2,453	11 Added 15.07%	84 $17,000
Q1 2022 May 12, 2022	BUY	$193.77 - $244.14 $8,719 - $10,986	45 Added 160.71%	73 $15,000
Q1 2021 May 10, 2021	BUY	$242.95 - $284.63 $6,802 - $7,969	28 New	28 $8,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Blume Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Blume Capital Management, Inc. with notifications on news.